2 Best Biotech Stocks to Buy Right Now
Biotech stocks have been on a wild ride in 2021. Thanks to a spate of surprise rejections by the Food and Drug Administration, an increasingly politicized regulatory landscape for COVID-19 vaccines, and widespread profit-taking in response to the industry's strong 2020, the SPDR S&P Biotech ETF initially lost over 12% of its value during the first six months of 2021.
However, this closely watched biotech ETF quickly sprang back to life last month in the wake of Pfizer's decision to buy cancer specialist Trillium Therapeutics. This early-stage buyout was widely regarded by investors as a positive sign that merger and acquisition activity within the industry could soon pick up in a big way, a central theme that ought to provide a much-needed boost for biotech valuations for the remainder of the year.
Image source: Getty Images.
Source Fool.com
